Navigation Links
Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics

Trophos Describes Identification, Characterization and Broad Neuroprotective Properties of TRO19622 in Journal of Pharmacology and Experimental Therapeutics

Neurodegenerative Disease Specialists Publish Details of a Novel Drug Candidate for ALS That Targets Mitochondrial Proteins

MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that a publication entitled "Identification and characterization of TRO19622 (cholest-4-en-3-one, oxime), a novel drug candidate for amyotrophic lateral sclerosis" has been accepted and published online May 11, 2007 in the Journal of Pharmacology And Experimental Therapeutics (J Pharmacol. Exp. Ther. 2007 May 11; [Epub ahead of print]).

Amylotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease in the USA, is a progressive and fatal neurological disease that is estimated to affect about 100,000 people worldwide. There is no cure for ALS. The only drug approved for ALS is riluzole (Rilutek(R), Sanofi-Aventis), which has been demonstrated to confer some survival benefit to ALS patients.

The studies reported in the paper by Bordet et al., (see below) identify two protein targets of TRO19622 present in the outer mitochondrial membrane suggesting that the compound has potential in a range of additional commercially attractive therapeutic indications involving mitochondrial dysfunction, including painful neuropathies. The publication describes the models of motor neuron disease employed to support the use of this compound to treat ALS, as well as spinal muscular atrophy. TRO19622 is currently in a Phase IIa clinical trial to establish its efficacy as a treatment for painful diabetic neuropathy.

TRO19622 is representative of novel compounds identified using the proprietary neuronal cell screening platform developed at Tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
8. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
9. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
10. JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:5/1/2015)... 2015  Misonix, Inc. (NASDAQ: MSON ), ... and markets innovative therapeutic ultrasonic products for spine ... laparoscopic surgery and other surgical applications, announced today ... third quarter fiscal year 2015 on Thursday, May ... call that same day, Thursday, May 7, 2015, ...
(Date:4/30/2015)... April 30, 2015 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the fourth ... Fourth quarter and fiscal 2015 overview: , ... fourth quarter, up 33% over last year,s comparable quarter, ... , Diluted EPS of $0.50 for the fourth ...
(Date:4/30/2015)... 2015  Thoratec Corporation (NASDAQ: THOR ), a ... support and restore failing hearts, said today it will ... Healthcare Conference on Thursday, May 14. ... will provide an update on the company, beginning at ... Time). The presentation will be available through ...
Breaking Medicine Technology:Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2
... 11 CryoLife, Inc. (NYSE: CRY ), ... announced today that Steven G. Anderson, president and chief executive ... upcoming Lazard Capital Markets Sixth Annual Healthcare Conference on Wednesday, ... City. CryoLife,s live presentation may be accessed through its ...
... PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today ... MuGard, an FDA approved treatment for oral mucositis, a debilitating ... to commercially launch MuGard in North America in the first ... launch include: , Manufacturing : Access is ...
Cached Medicine Technology:CryoLife to Present at Upcoming Investor Conferences in New York 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 4
(Date:5/2/2015)... 02, 2015 On Tuesday April 7th, ... (ELCH) gathered to celebrate improvements in patient care. In ... Partners (RVHP), had zero acquired ventilator associated infections, zero ... infections. ELCH was also recently named a Top Performer ... at ELCH credited the teamwork of staff from all ...
(Date:5/2/2015)... 02, 2015 With the success that Veatch ... proud to welcome Neida Miranda and Alex Shields to the ... has over 41 years of combined experience working with dentists ... the dental field for 8 years. She was certified ... Texas. Customer service, positive attitude and showing the importance of ...
(Date:5/1/2015)... May 01, 2015 Jusuru International has ... the successful repositioning of its flagship nutritional supplement, Liquid ... with a new name, new logo, new packaging, new ... Awards are designed to identify and promote programs that ... , “DSA congratulates Jusuru International for their outstanding ...
(Date:5/1/2015)... 2015 It’s raining bills on Capitol Hill ... to expand federal support for telemedicine. , “Such ... been working with Congress,” said Jonathan Linkous, CEO of the ... nation is poised to embrace the use of telecommunications in ... in fulfilling ATA’s mission to improve quality, access, equity and ...
(Date:5/1/2015)... 2015 The Quail Creek Relay for Life ... Since 2001, the Quail Creek Relay team has raised almost ... throughout the year, including their biggest event, January’s Dinner and ... , Quail Creek Relay for Life team was established ... Kerwin, fitness director, states, “I was hooked when I learned ...
Breaking Medicine News(10 mins):Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2
... Controversial food byproduct even showed protection for women, study ... a food byproduct that some research has linked to ... in men and may even offer slight protection for ... included more than 120,000 men and women, Dutch researchers ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ... invited to listen to the conference call that will be ... at 4:30 pm Eastern Time (1:30 pm Pacific Time).A live ... DURECT,s homepage at http://www.durect.com ...
... , , CHICAGO , April 28 ... Association,s (AUA) Annual Conference show that RAPAFLO (TM) ... both irritative and obstructive urinary symptoms associated with BPH, ... days of starting treatment. RAPAFLO (TM) ...
... statin medications have been found to have numerous other ... developing advanced prostate cancer, as well as lowering his ... by researchers at Henry Ford Hospital finds that statins ... cancer, potentially altering the results of a patient,s PSA ...
... Honored by Massachusetts LegislatureBEDFORD, Mass., April 28 ... visual impairment or his diabetes keep him from sailing ... members from the Carroll Center for the Blind in ... Division at the 2009 Blind Sailing World Championship Regatta ...
... Rules and Silences Opposition DebateCHESAPEAKE, Va., April 28 ... they will lack the necessary 60 votes required ... House and Senate Democrats last night struck a ... meaningful debate and drops the number of needed ...
Cached Medicine News:Health News:Acrylamide Doesn't Raise Lung Cancer Risk 2Health News:Acrylamide Doesn't Raise Lung Cancer Risk 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 2Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 4Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 5Health News:Statins alter prostate cancer patients' PSA levels 2Health News:Insulet Applauds Employee for Bronze Medal Performance in World Blind Sailing Championships 2Health News:Fast-Track of Socialized Healthcare Imminent 2
... Finnpipette Focus multichannel pipettes ... of reagents into microplates, ... 0.1-10 l volumes. The ... Finnpipette Focus multichannels, combined ...
... Research pro Electronic Pipette is ideal for ... Its easy-to-follow display, ergonomically-placed operating buttons, and ... reverse pipetting and diluting make this a ... functions of a manual pipette without any ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
Medicine Products: